The primary objectives of this study were to evaluate toxicity of escalating doses of prostate bed SBRT and provide dose recommendations for phase II study.
Patients with organ-confined, node-negative prostate cancer who had biochemical failure (Prostate-specific antigen [PSA] less than 2.